Literature DB >> 24297084

A systematic review of the characteristics associated with recall rates, detection rates and positive predictive values of computed tomography screening for lung cancer.

A Seigneurin1, J K Field2, A Gachet3, S W Duffy4.   

Abstract

BACKGROUND: Low-dose computed tomography (LDCT) screening has been shown to reduce mortality from lung cancer but at a substantial cost in diagnostic activity. The objective of this study was to investigate the characteristics of screening programmes associated with recall rates, detection rates and positive predictive values (PPVs).
DESIGN: We conducted a systematic review of randomised trials and observational studies on LDCT screening for lung cancer. A meta-regression using random-effect logistic regressions was carried out to assess factors influencing recall rates for further investigation, cancer detection rates and PPVs of recall.
RESULTS: We used data from 63 372 prevalent screens from 16 studies of LDCT screening for lung cancer and 79 302 incident screens from nine studies. In univariable analysis, the use of a cut-off size to define nodules warranting further investigation at prevalent screens reduced recall rates [odds ratio (OR) = 0.44, 95% confidence interval (CI) 0.24-0.82 and OR = 0.42, 95% CI 0.21-0.84 for cut-off sizes of 3-4 and 5-8 mm, respectively], without significant changes in detection rates and PPVs. The number of readers (1 or ≥2) was not associated with changes in recall rates, detection rates and PPVs at prevalent and incident screens. Using the volumetry software at incident screens significantly increased the PPV (OR = 5.02, 95% CI 1.65-15.28) as a result of a decrease in recall rates (OR = 0.25, 95% CI 0.12-0.51), without significant changes in detection rates.
CONCLUSION: These results highlight the value of using a cut-off size for nodules warranting further investigation with lower recall rates at prevalent screens, whereas the volumetric assessment software at incident screens results in lower recall rates and higher PPVs. The presence of positron emission tomography in the work-up protocol might be associated with lower rates of surgical procedures for benign findings, although this hypothesis deserves further investigation.

Entities:  

Keywords:  X-ray computed; lung neoplasms; mass screening; review; tomography

Mesh:

Year:  2013        PMID: 24297084     DOI: 10.1093/annonc/mdt491

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  7 in total

1.  Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada.

Authors:  Alexander V Louie; George B Rodrigues; David A Palma; Suresh Senan
Journal:  Oncologist       Date:  2014-06-20

Review 2.  The narrow path to organized LDCT lung cancer screening programs in Europe.

Authors:  Eugenio Paci
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  Contrast-enhanced computerized tomography combined with a targeted nanoparticle contrast agent for screening for early-phase non-small cell lung cancer.

Authors:  Ninglu Yuan; Xiaohe Zhang; Yonghui Cao; Xiaojie Jiang; Si Zhao; Yingying Feng; Yimeng Fan; Zhitao Lu; Hongmei Gao
Journal:  Exp Ther Med       Date:  2017-09-19       Impact factor: 2.447

4.  Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen.

Authors:  Nicola Sverzellati; M Silva; G Calareso; C Galeone; A Marchianò; S Sestini; G Sozzi; U Pastorino
Journal:  Eur Radiol       Date:  2016-02-11       Impact factor: 5.315

5.  Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression.

Authors:  Hongxia Li; Li Tong; Hong Tao; Zhe Liu
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

6.  Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom.

Authors:  S W Duffy; J K Field; P C Allgood; A Seigneurin
Journal:  Br J Cancer       Date:  2014-02-13       Impact factor: 7.640

7.  Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.

Authors:  Yun Zhang; Jing Wang; Zhuang Yu; Hong Ge; Lin-Wei Zhang; Ling-Xin Feng
Journal:  Clin Transl Sci       Date:  2021-01-25       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.